<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123667">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492608</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2011-000735-80</org_study_id>
    <secondary_id>Projectnumber 2010-382</secondary_id>
    <nct_id>NCT01492608</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate for Preterm Birth (MASP Study)</brief_title>
  <acronym>MASP</acronym>
  <official_title>Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess whether magnesium sulphate for women at risk of
      preterm birth can protect their children against cerebral palsy. The results from this
      randomised controlled trial will be added to the previous meta-analysis to obtain firm
      evidence for magnesium sulphate as a neuroprotector, and determine whether it should be used
      as standard therapy for women in preterm birth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral palsy consists of chronic and non-progressive clinical syndromes that are
      characterized by motor and postural dysfunction. In affected infants, voluntary movements
      become difficult and limited, and although clinical expression may change with time, this
      disability is accompanied with major personal and socioeconomic burdens. Preterm infants
      have increased risk of cerebral palsy, which is inversely correlated with gestational age at
      birth. Previous studies have indicated that magnesium sulphate may be neuroprotective for
      the preterm infant, when the drug is given to women prior to preterm birth. However, this
      benefit of antenatal magnesium sulphate was recently questioned by Trial Sequential Analysis
      (TSA), a statistical method that adjusts for risk of random error on published
      meta-analyses. TSA demonstrates that additional data are needed before accepting magnesium
      sulphate as evidence based therapy for women in preterm labour. Therefore we will close the
      gap by performing a new randomised clinical trial (RCT), which aims to assess whether
      magnesium sulphate for women prior to preterm birth can protect their children against
      cerebral palsy. The RCT will not individually have the power to detect a significant
      difference between magnesium and placebo. Instead, when the trial is completed, the results
      will be added to the previous meta-analysis to obtain firm evidence for magnesium sulphate
      as a neuroprotector, and determine whether it should be used as standard therapy for women
      in preterm birth.

      From Denmark 500 eligible women, who are at risk of preterm birth at 24 to 32 weeks of
      gestation, will be randomised to receive either intravenous magnesium sulphate or placebo.
      Randomisation will be performed blinded by computer generated random numbers.The children
      are followed up after 18 months of age by forwarding a standardized developmental
      questionnaire to the parents. If signs of cerebral palsy are suspected from the
      questionnaire, the children will be examined neurologically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate or severe cerebral palsy</measure>
    <time_frame>At 18 months of age</time_frame>
    <description>The difference in the number of children with moderate or severe cerebral palsy at 18 months of age, whose mothers had magnesium sulphate before birth compared to the group of children whose mothers received placebo before birth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perinatal death</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 18 months</time_frame>
    <description>The difference in the number of children with perinatal death, whose mothers had magnesium sulphate before birth compared to the group of children whose mothers received placebo before birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blindness</measure>
    <time_frame>At 18 months of age</time_frame>
    <description>The difference in the number of children with blindness at 18 months of age, whose mothers had magnesium sulphate before birth compared to the group of children whose mothers received placebo before birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar scores</measure>
    <time_frame>At 1 minute and 5 minutes after birth</time_frame>
    <description>The difference in apgar scores in the group of children, whose mothers had magnesium sulphate before birth compared to the group of children whose mothers received placebo before birth.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natriumchlorid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_label>Natriumchlorid</arm_group_label>
    <other_name>Magnesium sulfat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age 24+0-31+6 weeks

          -  Singletons or twins

          -  Preterm rupture of membranes at 24+0-31+6 weeks with contractions and expected birth
             within 2-24 hours

          -  Preterm contractions and expected birth within 2-24 hours

          -  Anticipated delivery within 2-24 hours of other reasons (due to for example fetal
             growth restriction)

          -  Age 18 years at inclusion

        Exclusion Criteria:

          -  Major fetal abnormalities or fetal death. (Major fetal abnormalities are chromosome
             abnormalities, myelomeningocele and cerebral abnormalities that gives neurological
             handicaps)

          -  Maternal contraindication to magnesium sulphate (for example pulmonary disorders,
             kidney diseases with creatinin &gt; 100, myasthenia gravis, atrioventricular block,
             treatment with aminoglycosides)

          -  Magnesium sulphate given for other reasons (for example for prevention of eclampsia)

          -  Patients who do not speak and understand Danish

          -  Allergies towards magnesium sulphate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Jørgen Secher, MD,Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology and Obstetrics, Hvidovre Hospital, Copenhagen University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lene Huusom, MD</last_name>
    <phone>++45 6016 0405</phone>
    <email>lene.huusom@mail.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Jørgen Secher, MD,Professor</last_name>
    <phone>++45 2622 8019</phone>
    <email>njsecher@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gynækologisk afdeling D</name>
      <address>
        <city>Odense</city>
        <state>Fyn</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bodil Andersen, MD</last_name>
      <phone>++45 6611 3333</phone>
      <email>bodilandersen@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Bodil Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-obstetrisk afdeling Y</name>
      <address>
        <city>Aarhus</city>
        <state>Jylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jannie Salvig, MD</last_name>
      <phone>++45 8949 6300</phone>
      <email>jannsalv@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Jannie Salvig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk obstetrisk Afdeling</name>
      <address>
        <city>Esbjerg</city>
        <state>Jylland</state>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels Kragsig Thomsen, MD</last_name>
      <phone>++45 7918 2714</phone>
      <email>troels.kragsig.thomsen2@svs.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Troels Kragsig Thomsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-obstetrisk afd.</name>
      <address>
        <city>Kolding</city>
        <state>Jylland</state>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Vind Olesen, MD</last_name>
      <phone>++45 7636 2000</phone>
      <email>annette.wind.olesen@slb.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Annette Vind Olesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk obstetrisk afdeling</name>
      <address>
        <city>Randers</city>
        <state>Jylland</state>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Ledertoug, MD</last_name>
      <phone>++45 7842 1060</phone>
      <email>susalede@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Susanne Ledertoug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-obstetrisk afd.</name>
      <address>
        <city>Silkeborg</city>
        <state>Jylland</state>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Boris, MD</last_name>
      <phone>++45 8722 2555</phone>
      <email>janebori@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Jane Boris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kvindeafdeling Y</name>
      <address>
        <city>Viborg</city>
        <state>Jylland</state>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linn Helleland, MD</last_name>
      <phone>++45 7844 5746</phone>
      <email>Linn.Elisabeth.Helleland@Viborg.RM.dk</email>
    </contact>
    <investigator>
      <last_name>Linn Helleland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-Obstetrisk Afdeling</name>
      <address>
        <city>Ålborg</city>
        <state>Jylland</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margrethe Møller, MD</last_name>
      <phone>++435 9932 1111</phone>
      <email>margr@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Margrethe Møller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obstetrisk Klinik</name>
      <address>
        <city>Copenhagen</city>
        <state>Sjælland</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Sharif, MD</last_name>
      <phone>++45 3545 3545</phone>
      <email>heidi_sharif@yahoo.dk</email>
    </contact>
    <investigator>
      <last_name>Heidi Sharif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk Obstetrisk afdeling</name>
      <address>
        <city>Herlev</city>
        <state>Sjælland</state>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henriette Jensen, MD</last_name>
      <phone>++45 3868 3868</phone>
      <email>henriettehjensen@yahoo.dk</email>
    </contact>
    <investigator>
      <last_name>Henriette Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-Obstetrisk Afdeling</name>
      <address>
        <city>Hillerød</city>
        <state>Sjælland</state>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Cathrine Shalmi, MD</last_name>
      <phone>++45 4829 4829</phone>
      <email>ash@noh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Anne Cathrine Shalmi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk Obstetrisk afdeling</name>
      <address>
        <city>Holbæk</city>
        <state>Sjælland</state>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Aabakke, MD</last_name>
      <phone>++45 5948 4252</phone>
      <email>anae@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Anna Aabakke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk Obstetrisk afdeling</name>
      <address>
        <city>Hvidovre</city>
        <state>Sjælland</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lene Huusom, MD</last_name>
      <phone>++45 60160405</phone>
      <email>lene.huusom@mail.dk</email>
    </contact>
    <investigator>
      <last_name>Lene Huusom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-obstetrisk afdeling</name>
      <address>
        <city>Næstved</city>
        <state>Sjælland</state>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Jønsson, MD</last_name>
      <phone>++45 5651 4082</phone>
      <email>ljos@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Lisbeth Jønsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynækologisk-obstetrisk afdeling</name>
      <address>
        <city>Roskilde</city>
        <state>Sjælland</state>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Lyndrup, MD</last_name>
      <phone>++45 4632 3200</phone>
      <email>jlyndrup@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Jens Lyndrup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology</name>
      <address>
        <city>Reykjavik</city>
        <zip>IS-101</zip>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reynir Geirsson, MD</last_name>
      <phone>+354 543 1000</phone>
      <email>geirsson.acta@landspitali.is</email>
    </contact>
    <investigator>
      <last_name>Reynir Geirsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kvinne-barn senteret</name>
      <address>
        <city>Tronheim</city>
        <zip>Postboks 3250</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bjørn Backe, MD</last_name>
      <phone>+47 815 55 850</phone>
      <email>bjorn.backe@ntnu.no</email>
    </contact>
    <investigator>
      <last_name>Bjørn Backe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Obstetrics and Gynecology</name>
      <address>
        <city>Malmø</city>
        <zip>S-20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Per Olufsson, MD</last_name>
      <phone>++46 4033 1000</phone>
      <email>Per.Olofsson@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Per Olufsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Huusom LD, Secher NJ, Pryds O, Whitfield K, Gluud C, Brok J. Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants--but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysis. BJOG. 2011 Jan;118(1):1-5. doi: 10.1111/j.1471-0528.2010.02782.x.</citation>
    <PMID>21197681</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 22, 2016</lastchanged_date>
  <firstreceived_date>December 11, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Lene Huusom</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>magnesium sulphate</keyword>
  <keyword>preterm birth</keyword>
  <keyword>cerebral palsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
